Symbol="AFMD"
AssetType="Common Stock"
Name="Affimed NV"
Description="Affimed NV, a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. The company is headquartered in Heidelberg, Germany."
CIK="1608390"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="IM NEUENHEIMER FELD 582, 69120, HEIDELBERG, DE"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="76760000"
EBITDA="-108418000"
PERatio="None"
PEGRatio="0"
BookValue="0.662"
DividendPerShare="0"
DividendYield="0"
EPS="-0.73"
RevenuePerShareTTM="0.228"
ProfitMargin="0"
OperatingMarginTTM="-3.201"
ReturnOnAssetsTTM="-0.344"
ReturnOnEquityTTM="-0.763"
RevenueTTM="34065000"
GrossProfitTTM="41801000"
DilutedEPSTTM="-0.73"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.721"
AnalystTargetPrice="5.96"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="3.796"
PriceToBookRatio="0.923"
EVToRevenue="2.199"
EVToEBITDA="0.533"
Beta="2.344"
num_52WeekHigh="3.06"
num_52WeekLow="0.451"
num_50DayMovingAverage="0.62"
num_200DayMovingAverage="1.045"
SharesOutstanding="149339000"
DividendDate="None"
ExDividendDate="None"
symbol="AFMD"
open="0.50"
high="0.52"
low="0.48"
price="0.50"
volume="729680.00"
latest_trading_day="2023-08-18"
previous_close="0.51"
change="-0.01"
change_percent="-1.5686%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="78"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="22"
Volume_recent_avg="905924"
Change_recent_avg="-0.01"
Delta_recent_avg="0.07"
Variance_recent_avg="0.03"
Change_ratio_recent_avg="-1.21"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="22"
Aroon_momentum_negative="78"
image_negative_thumbnail_id_1="164"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0012.jpeg"
image_negative_thumbnail_id_2="1098"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0131.jpeg"
image_neutral_thumbnail_id_1="592"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0007.jpeg"
image_neutral_thumbnail_id_2="432"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Neutral_Landscape_0019.jpeg"
image_positive_thumbnail_id_1="629"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0079.jpeg"
image_positive_thumbnail_id_2="991"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0153.jpeg"
image_professor_thumbnail_id_1="1193"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0027.jpeg"
image_professor_thumbnail_id_2="1186"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0020.jpeg"
